Amino acid-linked platinum(II) compounds: non-canonical nucleoside preferences and influence on glycosidic bond stabilities.
Adenosine adduct
Amino acid-linked platinum(II) compounds
Cisplatin
Glycosidic bonds
Kinetics
Journal
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry
ISSN: 1432-1327
Titre abrégé: J Biol Inorg Chem
Pays: Germany
ID NLM: 9616326
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
31
05
2019
accepted:
14
07
2019
pubmed:
31
7
2019
medline:
16
7
2020
entrez:
31
7
2019
Statut:
ppublish
Résumé
Nucleobases serve as ideal targets where drugs bind and exert their anticancer activities. Cisplatin (cisPt) preferentially coordinates to 2'-deoxyguanosine (dGuo) residues within DNA. The dGuo adducts that are formed alter the DNA structure, contributing to inhibition of function and ultimately cancer cell death. Despite its success as an anticancer drug, cisPt has a number of drawbacks that reduce its efficacy, including repair of adducts and drug resistance. Some approaches to overcome this problem involve development of compounds that coordinate to other purine nucleobases, including those found in RNA. In this work, amino acid-linked platinum(II) (AAPt) compounds of alanine and ornithine (AlaPt and OrnPt, respectively) were studied. Their reactivity preferences for DNA and RNA purine nucleosides (i.e., 2'-deoxyadenosine (dAdo), adenosine (Ado), dGuo, and guanosine (Guo)) were determined. The chosen compounds form predominantly monofunctional adducts by reacting at the N1, N3, or N7 positions of purine nucleobases. In addition, features of AAPt compounds that impact the glycosidic bond stability of Ado residues were explored. The glycosidic bond cleavage is activated differentially for AlaPt-Ado and OrnPt-Ado isomers. Formation of unique adducts at non-canonical residues and subsequent destabilization of the glycosidic bonds are important features that could circumvent platinum-based drug resistance.
Identifiants
pubmed: 31359185
doi: 10.1007/s00775-019-01693-y
pii: 10.1007/s00775-019-01693-y
pmc: PMC6806012
doi:
Substances chimiques
Glycosides
0
Organoplatinum Compounds
0
Purine Nucleosides
0
Ornithine
E524N2IXA3
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
985-997Subventions
Organisme : NIGMS NIH HHS
ID : TL4 GM118983
Pays : United States
Références
Proteomics. 2011 Nov;11(21):4174-88
pubmed: 21972224
Anal Chem. 2009 May 1;81(9):3208-15
pubmed: 19364119
J Phys Chem B. 2017 Apr 27;121(16):4048-4060
pubmed: 28355483
Oncogene. 2003 Oct 20;22(47):7265-79
pubmed: 14576837
Dalton Trans. 2006 Aug 7;(29):3515-7
pubmed: 16855751
Chem Commun (Camb). 2009 Jan 7;(1):107-9
pubmed: 19082014
Phys Chem Chem Phys. 2017 Jul 21;19(27):17637-17652
pubmed: 28665436
J Biol Inorg Chem. 2008 Mar;13(3):421-34
pubmed: 18157731
Chem Res Toxicol. 2017 Apr 17;30(4):980-995
pubmed: 28282121
J Am Soc Mass Spectrom. 2017 Nov;28(11):2423-2437
pubmed: 28836109
Chem Biol Interact. 1980 May;30(2):151-69
pubmed: 7190076
Eur J Mass Spectrom (Chichester). 2019 Feb;25(1):16-29
pubmed: 30189754
Nucleic Acids Res. 2008 Jan;36(Database issue):D402-8
pubmed: 17984079
Toxicol Lett. 2014 Feb 10;225(1):43-7
pubmed: 24275384
J Am Chem Soc. 2007 Apr 25;129(16):5023-30
pubmed: 17402732
Toxicon. 2013 Jul;69:143-51
pubmed: 23454625
Curr Opin Chem Biol. 2016 Apr;31:153-9
pubmed: 27031926
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3611-6
pubmed: 12655051
Chem Res Toxicol. 2009 Nov;22(11):1747-60
pubmed: 19757819
Proc Natl Acad Sci U S A. 1961 May 15;47:653-69
pubmed: 13742736
Science. 1985 Oct 25;230(4724):412-7
pubmed: 4048939
J Am Chem Soc. 2002 Apr 24;124(16):4495-503
pubmed: 11960480
J Inorg Biochem. 2004 Oct;98(10):1578-84
pubmed: 15458819
J Biol Inorg Chem. 2006 Nov;11(8):974-90
pubmed: 16953416
Mutat Res. 2001 Jul 1;478(1-2):1-21
pubmed: 11406166
Chem Rev. 2007 May;107(5):1387-407
pubmed: 17455916
J Phys Chem B. 2016 Sep 1;120(34):8892-904
pubmed: 27494378
Cancer Ther. 2003;1:47-61
pubmed: 18185852
Chem Commun (Camb). 2017 Nov 28;53(95):12746-12749
pubmed: 29099140
Phys Chem Chem Phys. 2016 Jun 21;18(23):16021-32
pubmed: 27240654
Biochemistry. 1995 Jul 4;34(26):8474-80
pubmed: 7599137
J Am Soc Mass Spectrom. 2009 Sep;20(9):1759-67
pubmed: 19616966
Mass Spectrom Rev. 2001 Mar-Apr;20(2):61-87
pubmed: 11455562
EMBO J. 2002 Jun 3;21(11):2833-41
pubmed: 12032096
Inorg Chem. 2000 Dec 11;39(25):5603-13
pubmed: 11151361
J Am Chem Soc. 2009 Jul 8;131(26):9250-7
pubmed: 19566097
J Am Chem Soc. 2003 Nov 19;125(46):14082-92
pubmed: 14611245
Chem Res Toxicol. 2006 May;19(5):622-6
pubmed: 16696564
Biochemistry. 1985 Jan 29;24(3):707-13
pubmed: 4039603
Nat Rev Drug Discov. 2005 Apr;4(4):307-20
pubmed: 15789122
Chem Rev. 1999 Sep 8;99(9):2467-98
pubmed: 11749487
Chem Commun (Camb). 2014 Apr 18;50(30):3918-20
pubmed: 24413091
Biochemistry. 1982 Dec 21;21(26):6732-6
pubmed: 6891601
Nat Med. 2017 Apr;23(4):461-471
pubmed: 28263311
Eur J Biochem. 1983 Sep 15;135(2):343-9
pubmed: 6884369
J Am Soc Mass Spectrom. 2017 Dec;28(12):2602-2613
pubmed: 28924832
Carcinogenesis. 1992 Mar;13(3):425-31
pubmed: 1547533
Inorg Chem. 1996 Aug 14;35(17):5019-5026
pubmed: 11666709
J Biol Chem. 1987 Jun 15;262(17):8128-30
pubmed: 3036799
J Phys Chem B. 2018 Oct 4;122(39):9147-9160
pubmed: 30203656
Mutat Res. 2009 Aug;678(2):76-94
pubmed: 19465146
Cancer. 1977 Apr;39(4):1362-71
pubmed: 851939
Nucleic Acids Res. 2016 Jun 2;44(10):4978-87
pubmed: 27079977
Curr Biol. 2003 Jun 17;13(12):R482-4
pubmed: 12814567
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905